vipivotide tetraxetan   Click here for help

GtoPdb Ligand ID: 11982

Synonyms: PSMA-617 | PSMA617
Compound class: Synthetic organic
Comment: Vipivotide tetraxetan (PSMA-617) is a potent PSMA (prostate-specific membrane antigen) inhibitor [1], that was designed for the treatrment of PSMA-positive hormone-relapsed metastatic prostate cancer. It has a DOTA moiety (= tetraxetan) that acts as a radionuclide-chelating domain.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 25
Hydrogen bond donors 11
Rotatable bonds 32
Topological polar surface area 365.19
Molecular weight 1041.5
XLogP -1.13
No. Lipinski's rules broken 3
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(CN1CCN(CCN(CCN(CC1)CC(=O)O)CC(=O)O)CC(=O)O)NCC1CCC(CC1)C(=O)N[C@H](C(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@H](C(=O)O)CCC(=O)O)Cc1ccc2c(c1)cccc2
Isomeric SMILES C1CC(CCC1CNC(=O)CN1CCN(CCN(CCN(CC1)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)N[C@@H](Cc1cc2ccccc2cc1)C(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O
InChI InChI=1S/C49H71N9O16/c59-40(28-55-17-19-56(29-42(62)63)21-23-58(31-44(66)67)24-22-57(20-18-55)30-43(64)65)51-27-32-8-12-35(13-9-32)45(68)52-39(26-33-10-11-34-5-1-2-6-36(34)25-33)46(69)50-16-4-3-7-37(47(70)71)53-49(74)54-38(48(72)73)14-15-41(60)61/h1-2,5-6,10-11,25,32,35,37-39H,3-4,7-9,12-24,26-31H2,(H,50,69)(H,51,59)(H,52,68)(H,60,61)(H,62,63)(H,64,65)(H,66,67)(H,70,71)(H,72,73)(H2,53,54,74)/t32?,35?,37-,38-,39-/m0/s1
InChI Key JBHPLHATEXGMQR-VLOIPPKDSA-N
References
1. Benešová M, Schäfer M, Bauder-Wüst U, Afshar-Oromieh A, Kratochwil C, Mier W, Haberkorn U, Kopka K, Eder M. (2015)
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
J Nucl Med, 56 (6): 914-20. [PMID:25883127]